Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | ADH4 | P08319 | 1/20 | 0.41 |
| ▸ | ADH7 | P40394 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 9/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29291472 | 1.00 | TSHR (0.44) | TSHRGGPS1EPHX1ADH1BADH1C | |
| SCHEMBL574091 | 1.00 | TSHR (0.44) | TSHRGGPS1EPHX1ADH1BADH1C | |
| SCHEMBL29291478 | 1.00 | TSHR (0.44) | TSHRGGPS1EPHX1ADH1BADH1C | |
| SCHEMBL28620996 | 1.00 | TSHR (0.44) | TSHRGGPS1EPHX1ADH1BADH1C | |
| SCHEMBL811537 | 1.00 | TSHR (0.44) | TSHRGGPS1EPHX1ADH1BADH1C | |
| SCHEMBL2046476 | 1.00 | TSHR (0.44) | TSHRGGPS1EPHX1ADH1BADH1C | |
| SCHEMBL2573738 | 1.00 | TSHR (0.44) | TSHRGGPS1EPHX1ADH1BADH1C | |
| SCHEMBL12361093 | 1.00 | TSHR (0.44) | TSHRGGPS1EPHX1ADH1BADH1C | |
| SCHEMBL1068830 | 1.00 | TSHR (0.44) | TSHRGGPS1EPHX1ADH1BADH1C | |
| SCHEMBL6024112 | 1.00 | TSHR (0.44) | TSHRGGPS1EPHX1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0662965-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1995-07-19 | — | — | EP | claimed |
| US-5321031-A | Treating cardiovascular disorders | SCHERING CORPORATION (US) | 1994-06-14 | — | — | US | claimed |
| WO-1994006784-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | claimed |
| EP-1095947-B1 | NOVEL ANTIBACTERIAL COMPOUNDS | SANKYO CO (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-6844173-B2 | Strain of Streptomyces griseus | SANKYO COMPANY, LIMITED (JP) | 2005-01-18 | — | — | US | disclosed |
| CN-1181087-C | Novel antibacterial compounds | ������������ʽ���� | 2004-12-22 | — | — | CN | disclosed |
| EP-1319406-A1 | Novel antibacterial compounds | Sankyo Company, Limited (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-20030069204-A1 | Strain of streptomyces | SANKYO COMPANY LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| US-6472384-B1 | Antimicrobial compounds | SANKYO COMPANY, LIMITED (JP) | 2002-10-29 | — | — | US | disclosed |
| EP-1095947-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | Sankyo Company Limited (JP) | 2001-05-02 | — | — | EP | disclosed |
| US-5607931-A | AMIDES | SCHERING CORPORATION (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0662965-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1995-07-19 | — | — | EP | disclosed |
| US-5321031-A | Treating cardiovascular disorders | SCHERING CORPORATION (US) | 1994-06-14 | — | — | US | disclosed |
| WO-1994006784-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069204-A1 | Strain of streptomyces | O60361, CYP8B1, MRPS34 | TSHR 3757/4885GGPS1 147/4885EPHX1 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.